Mikko Lemola/iStock via Getty Images
UK diagnostics marketer Virax Biolabs (VRAX) has applied for a US IPO.
The company has not disclosed this Size and pricing of the proposed IPO. It hopes to list its shares on the Nasdaq under the symbol VRAX. Boustead Securities acts as Lead Bookrunner, according to his filing.
Virax is incorporated in the Cayman Islands but has the majority of its operations in the UK and Hong Kong. The Company also operates through subsidiaries in China, Singapore and the British Virgin Islands.
Virax markets medical and in vitro diagnostic products manufactured by third parties. The company sells diagnostics under the ViraxClear brand name, including COVID-19 tests. It also sells products such as personal protective equipment and infrared thermometers under the ViraxCare brand name.
The company also develops technologies for immunological profiling of viral diseases under the Virax Immune brand.
Virax reported a net loss of $673,000 on sales of $124,000 for 2021.
For more IPO news, visit SA’s IPO News page.
Comments are closed.